Two new mouse models of uterine cancer shed light on how this disease - the most common gynecological cancer in the U.S. - happens. Led by researchers at Baylor College of Medicine, the team of ...
In a recent study posted to the medRxiv* pre-print server, a team of researchers demonstrated the inhibitory action of integrin/transforming growth factor beta 1 (TGF-β1) inhibitor GLPG0187 on severe ...
Oncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022 14.12.2021 / 15:01 The issuer is solely responsible for the content of this ...
Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis NEW YORK & MONTREAL--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: ...
PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback